SE0000375L - Human intestinal Npt2B - Google Patents

Human intestinal Npt2B

Info

Publication number
SE0000375L
SE0000375L SE0000375A SE0000375A SE0000375L SE 0000375 L SE0000375 L SE 0000375L SE 0000375 A SE0000375 A SE 0000375A SE 0000375 A SE0000375 A SE 0000375A SE 0000375 L SE0000375 L SE 0000375L
Authority
SE
Sweden
Prior art keywords
npt2b
iii
fragments
polypeptide
cells
Prior art date
Application number
SE0000375A
Other languages
Unknown language ( )
English (en)
Other versions
SE0000375D0 (sv
SE523043C2 (sv
Inventor
Paul David Cannon
Suryanarayana Sankurati
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SE0000375D0 publication Critical patent/SE0000375D0/sv
Publication of SE0000375L publication Critical patent/SE0000375L/sv
Publication of SE523043C2 publication Critical patent/SE523043C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE0000375A 1999-02-09 2000-02-07 Humant intestinalt Npt2B SE523043C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11932199P 1999-02-09 1999-02-09

Publications (3)

Publication Number Publication Date
SE0000375D0 SE0000375D0 (sv) 2000-02-07
SE0000375L true SE0000375L (sv) 2000-08-10
SE523043C2 SE523043C2 (sv) 2004-03-23

Family

ID=22383760

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000375A SE523043C2 (sv) 1999-02-09 2000-02-07 Humant intestinalt Npt2B

Country Status (14)

Country Link
US (3) US6380374B1 (sv)
JP (2) JP2000245488A (sv)
AT (1) AT411759B (sv)
AU (1) AU741170B2 (sv)
BE (1) BE1014389A5 (sv)
CA (1) CA2296178C (sv)
CH (1) CH694588A5 (sv)
DE (1) DE10004815B4 (sv)
FR (1) FR2791348B1 (sv)
GB (1) GB2348645A (sv)
IE (1) IE20000117A1 (sv)
IT (1) ITMI20000200A1 (sv)
NL (1) NL1014331C2 (sv)
SE (1) SE523043C2 (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372321T3 (es) * 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
JP4999255B2 (ja) 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド オリゴヌクレオチド含有薬理学的組成物およびその使用
US20050004348A1 (en) * 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
US8802094B2 (en) * 2006-10-25 2014-08-12 Wisconsin Alumni Research Foundation Method of reducing phosphate absorption by administering orally an IgY anti-intestinal sodium phosphate cotransporter type 2B antibody
AU2007309026B2 (en) * 2006-10-26 2013-09-12 Aovatechnologies, Inc. Methods of reducing phosphate absorption
EP3002297B1 (en) 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
CN109310885B (zh) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b靶向抗体-药物缀合物及其使用方法
US11596694B2 (en) 2017-09-20 2023-03-07 Mersana Therapeutics, Inc. Compositions and methods for predicting response to NaPi2b-targeted therapy
BR112021002747A2 (pt) 2018-08-17 2021-08-10 Mersana Therapeutics, Inc. conjugados de anticorpo-fármaco e polímero direcionados a napi2b e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985604A (en) 1997-02-24 1999-11-16 Incyte Pharmaceuticals, Inc. Human sodium-dependent phosphate cotransporter
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)

Also Published As

Publication number Publication date
JP2003325189A (ja) 2003-11-18
GB2348645A (en) 2000-10-11
CA2296178C (en) 2004-05-04
ITMI20000200A0 (it) 2000-02-08
DE10004815A1 (de) 2000-10-12
US20090170122A1 (en) 2009-07-02
IE20000117A1 (en) 2000-09-06
NL1014331C2 (nl) 2003-06-03
AU741170B2 (en) 2001-11-22
BE1014389A5 (fr) 2003-10-07
NL1014331A1 (nl) 2000-08-10
CA2296178A1 (en) 2000-08-09
US7368530B2 (en) 2008-05-06
ATA1972000A (de) 2003-10-15
SE0000375D0 (sv) 2000-02-07
JP2000245488A (ja) 2000-09-12
SE523043C2 (sv) 2004-03-23
FR2791348A1 (fr) 2000-09-29
US6380374B1 (en) 2002-04-30
US7803562B2 (en) 2010-09-28
DE10004815B4 (de) 2010-01-21
GB0002665D0 (en) 2000-03-29
CH694588A5 (de) 2005-04-15
US20020156266A1 (en) 2002-10-24
AT411759B (de) 2004-05-25
AU1497900A (en) 2000-08-31
FR2791348B1 (fr) 2007-10-05
ITMI20000200A1 (it) 2001-08-08

Similar Documents

Publication Publication Date Title
Wingo et al. Function and structure of HK-ATPase in the kidney
Frey et al. The biosynthetic precursor of epidermal growth factor and the mechanism of its processing.
Yu et al. Intracellular assembly of human fibrinogen.
LU92524I2 (fr) Protéine ORF2 de circovirus porcin de type 2 et ses dérivés pharmaceutiquement acceptables (IngelvacCircoFLEX)
BR0113864A (pt) ácidos nucléicos tipo kcp isolados e suas proteìnas codificadas
Perides et al. Isolation of a large aggregating proteoglycan from human brain.
BR9815588A (pt) Genes que codificam enzimas para biossìntese de lignina e seus usos
Whitley et al. Sec‐independent translocation of a 100‐residue periplasmic N‐terminal tail in the E. coli inner membrane protein proW.
ME00314B (me) Anti-tnf antitijela, kompozicije, postupci i primjene
WO2002031134A3 (en) Novel serine protease genes related to dppiv
Yamagami Isolation of a choriolytic enzyme (hatching enzyme) of the teleost, Oryzias latipes
SE0000375L (sv) Human intestinal Npt2B
Winkelmann et al. A new myosin fragment: visualization of the regulatory domain
KR890001581A (ko) 조직인자 억제제
AU1831097A (en) Thyroid sodium/iodide symporter and nucleic acid encoding same
ATE384787T1 (de) Tripeptidyl-aminopeptidase
MXPA02008239A (es) Gen humano de la esquizofrenia.
Ma et al. Protein for Lp82 calpain is expressed and enzymatically active in young rat lens
Onizuka et al. Distribution of μ-calpain proenzyme in the brain and other neural tissues in the rat
Inoue et al. Immunohistochemical demonstration of chromogranin in endometrial carcinomas with argyrophil cells
EA009956B1 (ru) Внутриклеточный полипептид (cari) и способы его применения
DE69535091D1 (en) Humane prostacyclinsynthase
Delaunoy et al. Quantitative measurements of carbonic anhydrase (CAII) in the central nervous system of neurological mutant mice ‘jimpy’by radioimmunoassay
Kurabuchi et al. An unusual sexually dimorphic mosaic distribution of a subset of kallikreins in the granular convoluted tubule of the mouse submandibular gland detected by an antibody with restricted immunoreactivity
WO2002086113A3 (en) Enzyme and snp marker for disease

Legal Events

Date Code Title Description
NUG Patent has lapsed